Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Clin J Am Soc Nephrol. 2011 Oct;6(10):2508-15. doi: 10.2215/CJN.04610511. Epub 2011 Sep 8.
Autosomal dominant polycystic kidney disease (ADPKD) is associated with a substantial cardiovascular disease burden including early onset hypertension, intracranial aneurysms, and left ventricular hypertrophy (LVH). A 41% prevalence of LVH has been reported in ADPKD, using echocardiographic assessment of LV mass (LVM). The HALT PKD study was designed to assess the effect of intensive angiotensin blockade on progression of total kidney volume and LVM. Measurements of LVM were performed using cardiac magnetic resonance (MR).
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five hundred forty-three hypertensive patients with GFR >60 ml/min per 1.73 m(2) underwent MR assessment of LVM at baseline. LVM was adjusted for body surface area and expressed as LVM index (LVMI; g/m(2)).
Baseline BP was 125.1 ± 14.5/79.3 ± 11.6 mmHg. Average duration of hypertension was 5.79 years. Prior use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was present in 59.5% of patients. The prevalence of LVH assessed using nonindexed LVM (g) was 3.9% (n = 21, eight men and 13 women) and 0.93% (n = 5, one man and four women) using LVMI (g/m(2)). In exploratory analyses, the prevalence of LVH using LVM indexed to H(2.7), and the allometric index ppLVmass(HW), ranged from 0.74% to 2.23% (n = 4 to 12). Multivariate regression showed significant direct associations of LVMI with systolic BP, serum creatinine, and albuminuria; significant inverse associations with LVMI were found with age and female gender.
The prevalence of LVH in hypertensive ADPKD patients <50 years of age with short duration of hypertension, and prior use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is low. Early BP intervention in ADPKD may have decreased LVH and may potentially decrease cardiovascular mortality.
常染色体显性多囊肾病(ADPKD)与包括早期高血压、颅内动脉瘤和左心室肥厚(LVH)在内的大量心血管疾病负担有关。使用超声心动图评估左心室质量(LVM),报告 ADPKD 的 LVH 患病率为 41%。HALT PKD 研究旨在评估强化血管紧张素阻断对总肾脏体积和 LVM 进展的影响。使用心脏磁共振(MR)测量 LVM。
设计、地点、参与者和测量方法:543 名 GFR>60ml/min/1.73m2 的高血压患者在基线时接受 LVM 的 MR 评估。LVM 按体表面积进行调整,并表示为 LVM 指数(LVMI;g/m2)。
基线 BP 为 125.1±14.5/79.3±11.6mmHg。高血压的平均病程为 5.79 年。59.5%的患者既往使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂。使用未索引的 LVM(g)评估的 LVH 患病率为 3.9%(n=21,8 名男性和 13 名女性)和 0.93%(n=5,1 名男性和 4 名女性)使用 LVMI(g/m2)。在探索性分析中,使用 LVM 索引到 H(2.7)的 LVH 患病率和幂律指数 ppLVmass(HW)的患病率范围为 0.74%至 2.23%(n=4 至 12)。多元回归显示 LVMI 与收缩压、血清肌酐和蛋白尿呈显著正相关;与年龄和女性性别呈显著负相关。
在年龄<50 岁、高血压病程短、既往使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂的 ADPKD 高血压患者中,LVH 的患病率较低。ADPKD 中早期 BP 干预可能降低了 LVH,并可能降低心血管死亡率。